|
08 Apr 2008 |
Bristol-Myers Squibb Selects Isis Drug Targeting PCSK9 as Development Candidate for Prevention and Treatment of Cardiovascular Disease
|
|
07 Apr 2008 |
Danish biotech company's restorative Alzheimer's product has successfully been implanted in patients
|
|
07 Apr 2008 |
Targeted Genetics Acquires Rights to siRNA Development Program in Huntington's Disease From Sirna Therapeutics
|
|
01 Apr 2008 |
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
|
|
01 Apr 2008 |
Amorcyte Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction
|
|
31 Mar 2008 |
Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
|
|
31 Mar 2008 |
Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis Platform in HIV at Keystone Symposia
|
|
28 Mar 2008 |
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
|
|
20 Mar 2008 |
Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic
|
|
19 Mar 2008 |
Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
|
|
18 Mar 2008 |
Targeted Genetics Announces Completion of Dosing for the Phase 1/2 Clinical Trial of tgAAC94 for Inflammatory Arthritis
|
|
17 Mar 2008 |
Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients with TTP, a Rare, Life-Threatening Blood Disorder
|
|
14 Mar 2008 |
Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
|
|
13 Mar 2008 |
AstraZeneca signs drug delivery collaboration
|
|
13 Mar 2008 |
Arrowhead Subsidiary, Calando Pharmaceuticals, Submits IND for Clinical Trial with Targeted, Nano-Delivered RNAi Therapeutic for Cancer
|
|
12 Mar 2008 |
Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
|
|
12 Mar 2008 |
Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
|
|
11 Mar 2008 |
Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
|
|
06 Mar 2008 |
Oncolys BioPharma and Medigen Biotechnology Enters Strategic Alliance and License Agreement to Develop and Commercialize Telomelysin(R)(OBP-301) for a Potential New Treatment for Solid Tumors
|
|
04 Mar 2008 |
Pluristem Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease
|
|
29 Feb 2008 |
Phase II Clinical Trial of ALN-RSV01 Demonstrates Statistically Significant Anti-Viral Efficacy with an Approximately 40% Reduction in RSV Infection Rate and 95% Increase in Infection-Free Subjects
|
|
28 Feb 2008 |
AVONTEC announce results of a multiple dose clinical proof of concept study with its drug candidate AVT-01 decoy ODN in asthmatic patients
|
|
26 Feb 2008 |
Prochymal(TM) Demonstrates Lasting Benefit in Heart Attack
|
|
25 Feb 2008 |
Harvest Technologies announces patient enrollment has begun for a clinical trial in India using autologous adult stem cells to treat patients with non-reconstructible Critical Limb Ischemia (CLI) due to Peripheral Arterial Occlusive Disease (PAOD)
|
|
15 Feb 2008 |
OncoGenex Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trial with Second-Line Chemotherapy for Prostate Cancer
|
